tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Salarius Pharmaceuticals Ord Shs

DCOY
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
0.975USD
-0.080-7.58%
์ข…๊ฐ€ย 11-13 16:00๏ผˆET๏ผ‰
2.33M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

Salarius Pharmaceuticals Ord Shs ์ •๋ณด ํšŒ์‚ฌ

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. It is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The companyโ€™s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.

Salarius Pharmaceuticals Ord Shs ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ - -
ํšŒ์‚ฌ ์ด๋ฆ„- -
์ƒ์žฅ์ผ- -
CEO- -
์ง์› ์ˆ˜- -
์œ ํ˜•- -
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒ- -
์ฃผ์†Œ- -
๋„์‹œ- -
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†Œ- -
๊ตญ๊ฐ€- -
์šฐํŽธ ๋ฒˆํ˜ธ- -
์ „ํ™”- -
์›น์‚ฌ์ดํŠธ- -
์ข…๋ชฉ ์ฝ”๋“œ - -
์ƒ์žฅ์ผ- -
CEO- -

Salarius Pharmaceuticals Ord Shs์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Mark J. Rosenblum, CPA
Mr. Mark J. Rosenblum, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
11.36K
+85.21%
Mr. Peter Marschel
Mr. Peter Marschel
Chief Business Officer
Chief Business Officer
3.90K
--
Ms. Tess Burleson
Ms. Tess Burleson
Independent Director
Independent Director
2.00K
+99.90%
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Independent Director
Independent Director
2.00K
+99.90%
,
,
--
--
Dr. William K. McVicar, Ph.D.
Dr. William K. McVicar, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David J. Arthur
Mr. David J. Arthur
Director
Director
--
--
Dr. Paul I. Lammers, M.D.
Dr. Paul I. Lammers, M.D.
Independent Director
Independent Director
--
--
Mr. Arnold C. Hanish
Mr. Arnold C. Hanish
Independent Director
Independent Director
--
--
Ms. Maureen McEnroe
Ms. Maureen McEnroe
IR Contact Officer
IR Contact Officer
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Mark J. Rosenblum, CPA
Mr. Mark J. Rosenblum, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
11.36K
+85.21%
Mr. Peter Marschel
Mr. Peter Marschel
Chief Business Officer
Chief Business Officer
3.90K
--
Ms. Tess Burleson
Ms. Tess Burleson
Independent Director
Independent Director
2.00K
+99.90%
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Independent Director
Independent Director
2.00K
+99.90%
,
,
--
--
Dr. William K. McVicar, Ph.D.
Dr. William K. McVicar, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Salarius Pharmaceuticals Ord Shs์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Salarius Pharmaceuticals Ord Shs์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Mr. Mark J. Rosenblum, CPA

Salarius Pharmaceuticals Ord Shs(DCOY)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, Salarius Pharmaceuticals Ord Shs์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 24๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 63.48K๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 11.93%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ 34985.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ